{"id":"NCT01610284","sponsor":"Novartis Pharmaceuticals","briefTitle":"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor","officialTitle":"A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-07","primaryCompletion":"2015-04-29","completion":"2019-04-19","firstPosted":"2012-06-04","resultsPosted":"2020-06-18","lastUpdate":"2020-08-25"},"enrollment":1147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Fulvestrant","otherNames":[]},{"type":"DRUG","name":"BKM120","otherNames":[]},{"type":"DRUG","name":"BKM120 matching placebo","otherNames":[]}],"arms":[{"label":"BKM120 100mg + Fulvestrant","type":"EXPERIMENTAL"},{"label":"Placebo + Fulvestrant","type":"PLACEBO_COMPARATOR"}],"summary":"This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.","primaryOutcome":{"measure":"Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort","timeFrame":"Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years","effectByArm":[{"arm":"BKM120 100mg + Fulvestrant","deltaMin":6.9,"sd":null},{"arm":"Placebo + Fulvestrant","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.003"},{"comp":"OG000 vs OG001","p":"0.015"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":268,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Peru","Poland","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["30241001","28576675"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":146,"n":573},"commonTop":["Nausea","Fatigue","Hyperglycaemia","Diarrhoea","Aspartate aminotransferase increased"]}}